Emcure Pharmaceuticals Ltd (EMCURE) — Cash Flow-to-Debt Ratio
Emcure Pharmaceuticals Ltd (EMCURE) has a Cash Flow-to-Debt Ratio of 0.06x as of September 2025, meaning its operating cash flow of Rs2.56 Billion could theoretically repay 0% of its total liabilities (Rs45.09 Billion) in one year. See EMCURE free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Emcure Pharmaceuticals Ltd Cash Flow-to-Debt Ratio (2022–2026)
Historical debt coverage capacity for Emcure Pharmaceuticals Ltd across 5 annual periods. Also explore EMCURE shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Emcure Pharmaceuticals Ltd (2022–2026)
Year-by-year debt coverage analysis for Emcure Pharmaceuticals Ltd. For market capitalisation and broader financial context, see EMCURE market cap.
| Year | CF-to-Debt Ratio | Operating CF (INR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2026 | 0.18x | Rs8.51 Billion | Rs46.36 Billion | ▼ -22.6% |
| 2025 | 0.24x | Rs8.52 Billion | Rs35.91 Billion | ▲ +1.3% |
| 2024 | 0.23x | Rs10.97 Billion | Rs46.84 Billion | ▲ +26.2% |
| 2023 | 0.19x | Rs7.47 Billion | Rs40.23 Billion | ▼ -4.6% |
| 2022 | 0.19x | Rs7.68 Billion | Rs39.49 Billion | — |